A selective, competitive and orally active GABAB
antagonist. Displays an IC50
of 1.1 μ
M at GABAB
, approximately 60 times that of CGP 35348
(Cat. No. 1245) and no binding affinity for GABAA
at concentrations up to 100 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of Schering Plough Corporation
The pharmacology of SCH 50911: a novel, orally active GABA-B receptor antagonist.
Bolser et al.
Characterization of the antiabsence effects of SCH 50911, a GABAB receptor antagonist, in the lethargic mouse, γ-hydroxybutyrate, and pentylenetetrazole models.
Hosford et al.
J.Pharmacol. Exp.Ther., 1995;274:1399
The morpholino-acetic acid analogue Sch 50911 is a selective GABAB receptor antagonist in rat neocortical slices.
Ong et al.
Substituted morpholine-2S-acetic acid derivatives: SCH 50911 and related compounds as novel GABAB antagonists.
Blythin et al.
The citations listed below are publications that use Tocris products. Selected citations for SCH 50911 include:
Showing Results 1 - 9 of 9